A molecular signature of 8-immune-related differentially expressed genes (8-IRDEGs) is a promising biomarker that can help distinguish the prognosis and molecular and immune features of cholangiocarcinoma (CCA), according to a new study published in Frontiers in Oncology. It can also help individualize immunotherapy for patients.

Immune cell infiltration and mRNA expression are factors associated with the prognosis of CCA.

To be able to better predict the recurrence of the disease, a team of researchers from China conducted conducting multi-immune-related gene analyses. The team selected immune-related genes from 3 different databases and developed a multigene model using the least absolute shrinkage and selection operator regression model, which was significantly correlated with recurrence-free survival.


Continue Reading

The researchers found that the 8-IRDEGs model, which is composed of the RORA, CNTFR, COLEC10, TNFSF15, SRC, PDGFD, TUBB3, and PLXNB3 genes was better at predicting the clinical characteristics, immune dysfunction, and exclusion, and inflammation signature of tumors compared to single genes.

Read more about CCA prognosis

The researchers also reported that their model might involve a variety of cancer recurrence and metastasis-associated pathways. This supports the recurrence-free survival predictive ability of the signature, they said.

“The signature could reveal different gene mutations in low- or high-risk groups,” they wrote, “which might contribute to targeted therapy.”

Since the 8-IRDEGs signature reflects immune cell infiltration in each patient, it can help clinicians make personalize their immunotherapy plans. This can ensure no medical resource is wasted in providing the wrong therapy to the wrong patient.

“In future studies, we and other investigators ought to further validate the efficiency of this model designed for clinical trials, including predicting prognosis, individualized assessment of immune status and genetic mutations, and improving a personalized therapeutic schedule,” the researchers concluded.

Reference

Guo H, Qian Y, Yu Y, et al. An immunity-related gene model predicts prognosis in cholangiocarcinoma. Front Oncol. 2022;12:791867. doi:10.3389/fonc.2022.791867